| abstract |
The invention provides novel reagents and methods for detecting BCR-ABL or c-Abl kinase activity, and/or Abl signaling pathway activation in a cell or tissue, and discloses novel biomarkers relevant to Abl-mediated disease progression and therapeutic responsiveness, and provides predictive and detection methods based on the same. Phosphorylated BCR-ABL (Tyr245) and/or c-Abl (Tyr245), BCR-ABL (Tyr735) and/or c-Abl (Tyr735), Bcr (Tyr177), CRKL (Tyr207), Gab1 (Tyr627), PYK2 (Tyr402), Tyk2 (Tyr1054/1055), SHP2 (Tyr580), ERK1/2 (Thr202/Tyr204) and MEK1/2 (Ser217/221) have now been identified as relevant biomarkers of c-Abl pathway-mediated disease, and phospho-specific antibodies to these targets are provided. Kits for carrying out the methods of the invention are also provided. |